Blood omega-3 fatty acids and death from COVID-19: A pilot study.
Level 3 - non-randomized controlled study
Observational cohort study analyzing baseline biomarkers against clinical mortality
PubMed 33516093 · doi:10.1016/j.plefa.2021.102250
What was done
Analyzed red blood cell EPA+DHA levels (the Omega-3 Index, O3I) from banked blood samples drawn at hospital admission in a pilot cohort of 100 COVID-19 patients to evaluate the association with risk of death.
What was found
Overall, 14 of 100 patients died: 1 of 25 patients in quartile 4 (Q4, O3I ≥5.7%) compared to 13 of 75 patients in quartiles 1–3 (Q1–3). After adjusting for age and sex, the odds ratio for death in Q4 versus Q1–3 was 0.25 (p = 0.07).
Why it matters
Offers preliminary hypothesis-generating evidence that higher tissue omega-3 levels might be linked to lower mortality from COVID-19, though definitive confirmation in powered cohorts is needed.
Limits
Small sample size (n = 100 with only 14 deaths) leading to low statistical power and an estimate that did not meet classical statistical significance (p = 0.07). The observational design cannot prove causality, and adjustment was limited to age and sex without accounting for comorbidities or treatment differences in the abstract.
Cited by
- supports A pilot study of 100 COVID-19 patients admitted to Cedars-Sinai found that patients in the highest quartile of Omega-3 Index had approximately half the mortality risk of those in lower quartiles (p = 0.07).